1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma von Ludwig, J.A., Federman, N., Anderson, P., Macy, M.E., Davis, L.E., Riedel, R.F., Muscal, J.A., Daw, N.C., Ratan, R., Toretsky, J., Ianopulos, X., Hsu, F.J., Breitmeyer, J.B., Meyers, P.

Volltext